CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty
The advance trial
Marco Valgimigli, MD* ,*,
Gianfranco Percoco, MD*,
Dario Barbieri, MD*,
Fabrizio Ferrari, MD*,
Gabriele Guardigli, MD*,
Giovanni Parrinello, PhD ,
Olga Soukhomovskaia, MD* and
Roberto Ferrari, MD, PhD*
* Department of Cardiology, University of Ferrara, Ferrara, Italy
Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS Gussago (BS), Gussago, Italy
Medical Statistics Unit, University of Brescia, Brescia, Italy
Manuscript received January 28, 2004;
revised manuscript received February 24, 2004,
accepted March 2, 2004.
* Reprint requests and correspondence: Dr. Marco Valgimigli, Chair of Cardiology, University of Ferrara, Cardiovascular Institute, Arcispedale S. Anna Hospital, C.rso Giovecca 203, 44100 Ferrara, Italy.
vlgmrc{at}unife.it
OBJECTIVES: We sought to determine the safety and efficacy of high-dose bolus (HDB) tirofiban in high-risk patients undergoing percutaneous coronary intervention (PCI).
BACKGROUND: The use of HDB tirofiban in the catheterization laboratory is controversial. In particular, in patients with acute coronary syndromes undergoing PCI, there is no evidence that tirofiban administered in the catheterization laboratory is superior to heparin alone. This finding probably reflects the suboptimal platelet inhibition when tirofiban is employed at RESTORE (Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis) regimen.
METHODS: A total of 202 patients (mean age 69 ± 8 years; 137 males [68%]) undergoing high-risk PCI, pretreated with thienopyridines, were consecutively randomized to HDB tirofiban (25 µg/kg/3 min, and infusion of 0.15 µg/kg/min for 24 to 48 h) or placebo immediately before the procedure and then followed for a median time of 185 days (range 45 to 324 days) for the occurrence of the primary composite end point of death, myocardial infarction, target vessel revascularization (TVR), and bailout use of glycoprotein (GP) IIb/IIIa inhibitors.
RESULTS: The cumulative incidence of the primary end point was 35% and 20% in placebo and HDB tirofiban groups, respectively (hazard ratio 0.51, 95% confidence interval 0.29 to 0.88; p = 0.01). This difference was mainly due to the reduction of myocardial infarction and bailout use of GP IIb/IIIa inhibitors, with no significant effect on TVR or death. The safety profile did not differ between tirofiban and placebo.
CONCLUSIONS: The use of tirofiban, when administered at HDB, is safe and significantly reduces the incidence of ischemic/thrombotic complications during high-risk PCI.
|
Abbreviations and Acronyms
| | ACS | = acute coronary syndrome | | ACT | = activated clotting time | | CK | = creatine kinase | | GP | = glycoprotein | | HDB | = high-dose bolus | | MI | = myocardial infarction | | PCI | = percutaneous coronary intervention | | TVR | = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
J. M. O'Riordan, R. J. Margey, G. Blake, and P. R. O'Connell
Antiplatelet Agents in the Perioperative Period
Arch Surg,
January 1, 2009;
144(1):
69 - 76.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, G. Campo, G. Percoco, L. Bolognese, C. Vassanelli, S. Colangelo, N. de Cesare, A. E. Rodriguez, M. Ferrario, R. Moreno, et al.
Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial
JAMA,
April 16, 2008;
299(15):
1788 - 1799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bode and K. Huber
Antiplatelet therapy in percutaneous coronary intervention
Eur. Heart J. Suppl.,
January 1, 2008;
10(suppl_A):
A13 - A20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Eur. Heart J.,
July 1, 2007;
28(13):
1598 - 1660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dudek, A. Dziewierz, B. Chyrchel, L. Polonski, J. Legutko, and J. S. Dubiel
Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight)
Eur. Heart J. Suppl.,
February 1, 2007;
9(suppl_A):
A25 - A31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Bertrand and E. Van Belle
Triple antiplatelet treatment in patients presenting with non-ST-segment elevation acute coronary syndromes
Eur. Heart J. Suppl.,
October 1, 2006;
8(suppl_G):
G59 - G63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Ben-Yehuda
Upstream/Downstream: Glycoprotein IIb/IIIa in Non-ST-Segment Elevation Myocardial Infarction
J. Am. Coll. Cardiol.,
February 7, 2006;
47(3):
538 - 540.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bolognese, G. Falsini, F. Liistro, P. Angioli, K. Ducci, T. Taddei, R. Tarducci, F. Cosmi, S. Baldassarre, and A. Burali
Randomized Comparison of Upstream Tirofiban Versus Downstream High Bolus Dose Tirofiban or Abciximab on Tissue-Level Perfusion and Troponin Release in High-Risk Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions: The EVEREST Trial
J. Am. Coll. Cardiol.,
February 7, 2006;
47(3):
522 - 528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J.,
December 1, 2005;
26(23):
2493 - 2519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cavallini and F. Chirillo
Non-ST-elevation acute coronary syndromes management: a fresh look at glycoprotein IIb/IIIa inhibitors
Eur. Heart J. Suppl.,
October 1, 2005;
7(suppl_K):
K10 - K14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, G. Percoco, P. Malagutti, G. Campo, F. Ferrari, D. Barbieri, G. Cicchitelli, E. P. McFadden, F. Merlini, L. Ansani, et al.
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial
JAMA,
May 4, 2005;
293(17):
2109 - 2117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al.
Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Eur. Heart J.,
April 2, 2005;
26(8):
804 - 847.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Diamond
ADVANCE praise
J. Am. Coll. Cardiol.,
February 1, 2005;
45(3):
469 - 469.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli and P. W. Serruys
Reply
J. Am. Coll. Cardiol.,
February 1, 2005;
45(3):
469 - 469.
[Full Text]
[PDF]
|
|
|
|
